BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 25744474)

  • 1. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
    Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
    Lehtinen M; Apter D
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.
    Brisson M; Bénard É; Drolet M; Bogaards JA; Baussano I; Vänskä S; Jit M; Boily MC; Smith MA; Berkhof J; Canfell K; Chesson HW; Burger EA; Choi YH; De Blasio BF; De Vlas SJ; Guzzetta G; Hontelez JAC; Horn J; Jepsen MR; Kim JJ; Lazzarato F; Matthijsse SM; Mikolajczyk R; Pavelyev A; Pillsbury M; Shafer LA; Tully SP; Turner HC; Usher C; Walsh C
    Lancet Public Health; 2016 Nov; 1(1):e8-e17. PubMed ID: 29253379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM; Kjaer SK; Muñoz N; Block SL; Brown DR; DiNubile MJ; Lindsay BR; Kuter BJ; Perez G; Dominiak-Felden G; Saah AJ; Drury R; Das R; Velicer C
    Clin Infect Dis; 2016 Aug; 63(4):519-27. PubMed ID: 27230391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
    Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
    BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.
    Yakely AE; Avni-Singer L; Oliveira CR; Niccolai LM
    Sex Transm Dis; 2019 Apr; 46(4):213-220. PubMed ID: 30461595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
    BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
    Kim JJ
    Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the long-term effects of HPV vaccination in Germany.
    Horn J; Damm O; Kretzschmar ME; Deleré Y; Wichmann O; Kaufmann AM; Garbe E; Krämer A; Greiner W; Mikolajczyk RT
    Vaccine; 2013 May; 31(19):2372-80. PubMed ID: 23518405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
    Lukács A; Máté Z; Farkas N; Mikó A; Tenk J; Hegyi P; Németh B; Czumbel LM; Wuttapon S; Kiss I; Gyöngyi Z; Varga G; Rumbus Z; Szabó A
    BMC Public Health; 2020 May; 20(1):691. PubMed ID: 32460747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.